NEWS

​

JUNE 6, 2022

Xalud Therapeutics CEO to Participate in Two Gene Therapy Focused Panels at BIO International Convention 2022 

​

APRIL 25, 2022

Xalud Therapeutics, today announced the appointment of Amy Chappell, M.D., as an independent strategic advisor 

​

MARCH 2, 2022

Xalud Therapeutics Doses First Patient in Phase 2a Trial of XT-150 for the Treatment of Facet Joint Osteoarthritis Pain 

​

DECEMEBER 17, 2021

Xalud Therapeutics Receives FDA Fast Track Designation for XT-150 for the Treatment of Pain Associated with Osteoarthritis of the Knee

​

NOVEMBER 9, 2021

Xalud Therapeutics Appoints Charles Triano as Chief Financial Officer

​

AUGUST 23, 2021

Xalud Therapeutics Completes Oversubscribed $30 Million Series C Financing
 

JULY 13, 2021

Xalud Therapeutics Announces the Expansion of Its Strategic Advisors

​

MAY 20, 2021

Xalud Therapeutics’ Lead Candidate, XT-150, Achieves Multiple Clinical Milestones in Pathologic Inflammation and Neuroimmunology Therapeutic Areas 

​

MAY 11, 2021

Xalud Therapeutics Expands Leadership Team with Key Appointments

​

JANUARY 22, 2021

Xalud Therapeutics Appoints Diem Nguyen, Ph.D., as Chief Executive Officer

​